CEO SUMMARY: Miraca Life Sciences amended its merger agreement with Avista Capital Partners after the lab lost value in the two months since the agreement was signed in September. Factors precipitating the revision were a significant decline in reimbursement rates, stiff competition from physician-office labs (POLs), and a loss of specimen volume to POLs and […]
Value of Miraca Falls By 92% from 2011 to 2017
Variety of market forces push down lab’s value; is the same true at other independent lab firms?
- By Joseph Burns
- > From the Volume XXIV No. 17 - December 11, 2017 Issue
- Tags: Anatomic pathology, anatomic pathology lab, biopsies, biopsy, cap, clinical lab, clinical lab test, clinical lab testing, Clinical Laboratory, dark report, dermatopathology, diagnostics lab, hematology, Histology, impac, lab costs, lab operation, lab operations, lab process, lab test, lab test prices, lab testing, laboratories, laboratory company, lean method, lean methods, Medicare, molecular pathology, molecular pathology lab, pathologists, pathology lab, pathology laboratories, pathology test, prostate biopsy, the clinical laboratory, the dark report
